|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2006-11-20
|
|
pubmed:abstractText |
Alfentanil is a short-acting synthetic opioid analgesic, which is extensively metabolized, mainly by hepatic cytochrome P450 (CYP) 3A enzymes. Concomitant administration of alfentanil and CYP3A inhibitors may lead to clinically important drug interactions. We investigated the possible interactions between alfentanil and orally administered voriconazole and terbinafine.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Alfentanil,
http://linkedlifedata.com/resource/pubmed/chemical/Analgesics, Opioid,
http://linkedlifedata.com/resource/pubmed/chemical/Antifungal Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cytochrome P-450 CYP3A,
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Naphthalenes,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidines,
http://linkedlifedata.com/resource/pubmed/chemical/Triazoles,
http://linkedlifedata.com/resource/pubmed/chemical/terbinafine,
http://linkedlifedata.com/resource/pubmed/chemical/voriconazole
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0009-9236
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
80
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
502-8
|
|
pubmed:meshHeading |
pubmed-meshheading:17112806-Administration, Oral,
pubmed-meshheading:17112806-Adult,
pubmed-meshheading:17112806-Alfentanil,
pubmed-meshheading:17112806-Analgesics, Opioid,
pubmed-meshheading:17112806-Antifungal Agents,
pubmed-meshheading:17112806-Area Under Curve,
pubmed-meshheading:17112806-Color Vision Defects,
pubmed-meshheading:17112806-Cross-Over Studies,
pubmed-meshheading:17112806-Cytochrome P-450 CYP3A,
pubmed-meshheading:17112806-Drug Interactions,
pubmed-meshheading:17112806-Enzyme Inhibitors,
pubmed-meshheading:17112806-Female,
pubmed-meshheading:17112806-Half-Life,
pubmed-meshheading:17112806-Humans,
pubmed-meshheading:17112806-Injections, Intravenous,
pubmed-meshheading:17112806-Male,
pubmed-meshheading:17112806-Metabolic Clearance Rate,
pubmed-meshheading:17112806-Naphthalenes,
pubmed-meshheading:17112806-Photophobia,
pubmed-meshheading:17112806-Pyrimidines,
pubmed-meshheading:17112806-Sex Factors,
pubmed-meshheading:17112806-Triazoles,
pubmed-meshheading:17112806-Vomiting
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life.
|
|
pubmed:affiliation |
Department of Anesthesiology and Intensive Care, University of Turku, Turku, Finland. teijo.saari@tyks.fi
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
